Eva Muñoz‐Couselo

The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies

Luping Lin, Amit J. Sabnis, Elton Chan et al. · Nature Genetics · 2015 · 548 citations · Full text

Medicine, Mek-targeted Cancer Therapies, Hippo Effector Yap +8

Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial

Eric P. Winer, Oleg Lipatov, Seock‐Ah Im et al. · The Lancet Oncology · 2021 · 469 citations

Breast Oncology, Oncology, Clinical Trials +7

Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study

Peter Schmid, Roberto Salgado, Y.H. Park et al. · Annals of Oncology · 2020 · 423 citations

Phase 1B, Breast Oncology, Oncology +9

Initial efficacy of anti-lymphocyte activation gene-3 (anti–LAG-3; BMS-986016) in combination with nivolumab (nivo) in pts with melanoma (MEL) previously treated with anti–PD-1/PD-L1 therapy.

Paolo A. Ascierto, Ignacio Melero, Shailender Bhatia et al. · Journal of Clinical Oncology · 2017 · 238 citations

Immunology, Immune Regulation, Immunoediting +24

Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial

Brett Hughes, Eva Muñoz‐Couselo, Laurent Mortier et al. · Annals of Oncology · 2021 · 179 citations